Lumen Bioscience reports positive RePreve results for LMN-201, with higher global cure and lower C. difficile recurrence in a small randomized comparison.
Written By: Charvi Kalal, PharmD
Reviewed By: Pharmacally Editorial Team
Lumen Bioscience reported positive results on October 21, 2026, from the RePreve clinical trial of LMN-201, an investigational oral biologic cocktail for Clostridioides difficile infection (CDI). In the randomized, double-blind Part B comparison, global cure occurred in 83.3% of patients receiving LMN-201 alongside standard-of-care antibiotics, compared with 36.4% receiving placebo and antibiotics. The company reported statistical significance under its prespecified Bayesian analysis plan.
The findings will be presented at IDWeek 2026 in Washington, DC, on October 24. Although the results suggest potential to reduce CDI recurrence, the small randomized cohort limits the precision and generalizability of the findings.
How LMN-201 Targets C. difficile Infection
LMN-201 combines three toxin-binding proteins with an antibacterial enzyme, manufactured in engineered spirulina using Lumen’s proprietary production platform. Delivered in oral capsules, the investigational treatment is intended for use during and after antibiotic therapy to improve initial treatment outcomes and prevent recurrence.
The approach combines toxin neutralization with antibacterial activity. However, the reported clinical findings do not yet establish how much each component contributes to the observed treatment effect. LMN-201 remains investigational and has not been approved by regulators.
RePreve Trial Design and Key Results
Lumen reported results from 45 participants across Parts A and B of RePreve (NCT05330182), including 23 participants in the randomized Part B comparison. Part B used a 1:1 randomized, double-blind design, with stratification by standard-of-care antibiotic and age.
Global cure, the primary outcome, combined successful initial treatment with the absence of CDI recurrence. In Part B, 10 of 12 patients receiving LMN-201 achieved global cure, compared with four of 11 receiving placebo.
The absolute difference was 47 percentage points, with an odds ratio of 8.75. The company reported that the result met its prespecified Bayesian statistical criteria, although the announcement did not provide the analysis details needed to independently assess the statistical uncertainty.
Recurrence rates were 9.1% with LMN-201 plus antibiotics and 55.6% with placebo plus antibiotics. This difference is clinically relevant because recurrent CDI can lead to repeated treatment, additional healthcare use and further episodes of infection. Nevertheless, the small sample means the magnitude of the apparent benefit remains uncertain.
LMN-201 also reduced primary cure failure by more than 50% relative to standard-of-care treatment alone, with an odds ratio of 0.425. This secondary endpoint showed a favorable trend but did not reach statistical significance. The findings therefore do not establish a significant improvement in initial treatment success independently of recurrence prevention.
Safety Findings and Evidence Limitations
Lumen reported that LMN-201 was well tolerated, with adverse-event rates similar to placebo and consistent with the underlying infection and initial antibiotic treatment. No drug-related serious adverse events or deaths were reported.
However, the announcement did not provide detailed adverse-event counts or sufficient information to assess less common risks. The small randomized population also limits the ability to characterize safety reliably.
The results remain based on a company announcement, with manuscripts for RePreve and an earlier study of safety, tolerability and gastrointestinal pharmacokinetics in preparation. The full clinical presentation and subsequent peer-reviewed publication will be important for evaluating the findings.
Clinical Interpretation and Next Steps
RePreve provides an encouraging early clinical signal for an oral biologic designed to address both treatment outcomes and recurrence in CDI. The substantial reported difference in global cure, alongside lower recurrence, supports further investigation of LMN-201 as an adjunct to standard antibiotic therapy.
The evidence remains preliminary. Only 23 patients contributed to the randomized comparison, the secondary endpoint of primary cure failure was not statistically significant, and the announcement did not provide detailed uncertainty intervals for the recurrence result.
Further evaluation should establish the durability of recurrence prevention, provide complete safety and efficacy data, and compare outcomes with established treatment strategies.
For now, LMN-201 should be regarded as an investigational approach with promising but unconfirmed clinical benefit. Larger, fully reported datasets will be necessary to determine whether the observed results translate into a meaningful improvement in CDI management.
References
Lumen Bio Reports Positive Phase 2 Results from the RePreve Clinical Trial (LMN-201 for C. difficile Infection), Lumen Bioscience, 21 October 2026
LMN-201 for Prevention of C. Difficile Infection Recurrence, ClinicalTrials.gov ID NCT05330182
About the Writer
Charvi Kalal (LinkedIn) is a Pharm.D intern and aspiring medical writer with hands-on experience in medical writing, clinical research, pharmacovigilance, and clinical pharmacy. She has experience in medical content writing through CliMed, along with exposure to ADR monitoring, prescription analysis, patient counselling, literature review, and research documentation. Her research focuses on ADR monitoring and reporting in breast cancer patients receiving targeted therapy. With certifications in GCP, biomedical research, scientific writing, and clinical research, she is passionate about transforming scientific evidence into accurate, engaging, and accessible healthcare content.